

Members Obtain Free CE Credits from JCP Articles!



Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease

July 2025 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Learners who complete this course will gain an enhanced understanding of the pharmacokinetics and safety profile of fenofibrate in patients with varying degrees of hepatic function including those with mild hepatic impairment and those with advanced fibrosis due to metabolic-associated fatty liver disease (MAFLD). This knowledge will support clinical decision-making and the safe evidence-informed use of fenofibrate in complex patient populations.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-25-026-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME
ACCREDITED

ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in expanding their knowledge on fenofibrate use in patients with hepatic dysfunction.

Learning Objectives

After completing this activity, the learner will be able to:

1. Identify changes in pharmacokinetics of fenofibrate in patients with mild hepatic dysfunction;
2. Describe challenges for the use of fenofibrate in patients with hepatic dysfunction;
3. Apply fenofibrate safely in patients with metabolic-associated fatty liver disease and hepatic dysfunction.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.

Planner: Sandeep Kaushal, MD, Professor & Head, Dayanand Medical Coll & Hosp, planned the continuing education documentation for this course and has nothing to disclose.

CE Reviewer: Ahmed Abulfathi, MBBS, MMed, FCCP, PhD, Scientist/Pharmacometrics, employed at Certara US Inc, served as the CE Reviewer and all of the relevant financial relationships have been mitigated.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 7/1/2025

Expiration Date: 7/1/2028

Online Location:

https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14